Lantheus MI Real Estate, LLC Watch

from S-4 14 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Amendment No. 4 to the Agreement Concerning Cardiolite® and Technelite® Generator Supply, Pricing and Rebates

from S-4/A 33 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Distribution Agreement

from S-4/A 9 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Amendment No. 3 to the Agreement Concerning Cardiolite® and Technelite® Generator Supply, Pricing and Rebates

from S-4/A 16 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Amendment No. 2 to the Agreement Concerning Cardiolite® and Technelite® Generator Supply, Pricing and Hebates

from S-4/A 5 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission Amendment No. 1 to the Agreement Concerning Cardiolite® and Technelite® Generator Supply, Pricing and Rebates

from S-4/A 26 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. Pages 26 – 33 in Exhibit 1.1(q) Have Been Omitted and Noted With “****” Based on a Request for Confidential Treatment. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission

from S-4/A 33 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Distribution Agreement

from S-4/A 16 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Agreement Concerning Cardiolite® and Technelite® Generator Supply, Pricing and Rebates

from S-4/A 19 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission

from S-4/A 38 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission

from S-4/A 17 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Execution Version / Nordion Doc # 84734 Molybdenum-99 Purchase & Supply Agreement

from S-4/A 27 pages The Parties: Recitals

from S-4/A 3 pages (A) Cov (Or Any Appropriately Licensed and Qualified Affiliates, Approved in Advance by Writing by Lmi, Such Approval Not to Be Unreasonably Withheld or Delayed) Shall Manufacture, Sell and Deliver to Lmi, and Lmi Shall Purchase From Cov, Either Drug Substance or the Product on the Terms and Conditions and in the Quantities Set Forth in This Agreement. 1.2. Section 2.1 (B) of the Agreement Is Hereby Amended by Deleting in Its Entirety Said Section 2.1(b) and Replacing Therewith the Following: (B) Subject to the Provisions of Section 2.4 Below, Lmi Will Purchase Either Drug Substance or Product From Cov During the Term. 1.3. the First Sentence of Section 2.4 Is Hereby Amended by Deleting in Its Entirety Said First Sentence and Replacing Therewith the Following

from S-4/A 23 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission

from S-4/A 2 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Amendment No. 1 to Amended and Restated Supply Agreement

from S-4/A 1 page To: Lantheus Medical Imaging October 19, 2008 /S/ Larry G Pickering Larry G Pickering Executive Chairman, Lantheus Medical Imaging CC: David Burgstahler, Avista Capital Michael Duffy, Legal Counsel Bob Gaffey, CFO

from S-4/A 9 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. First Amendment to Distribution Agreement

from S-4/A 18 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission. Distribution Agreement

from S-4/A 16 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission

from S-4/A 27 pages Information for Which Confidential Treatment Has Been Requested Is Omitted and Noted With “****”. an Unredacted Version of This Document Has Also Been Provided to the Securities and Exchange Commission